<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260973</url>
  </required_header>
  <id_info>
    <org_study_id>PRN 20145</org_study_id>
    <nct_id>NCT02260973</nct_id>
  </id_info>
  <brief_title>The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity</brief_title>
  <official_title>The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity Outcomes In Cases Undergoing Cataract Surgery: A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Physician Recommended Nutriceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Physician Recommended Nutriceuticals</source>
  <brief_summary>
    <textblock>
      This is a randomized, masked, placebo controlled study to assess the effect on visual acuity,
      if any, of the PRN omega-3 nutritional supplement in subjects undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cataract, Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>re esterified TG omega-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safflower Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vegetable oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 (Triglyceride form)</intervention_name>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_label>Safflower Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of nuclear or cortical lens opacities in one/both eyes

          -  Physician diagnosis of age related cataract

          -  Good overall physical constitution

          -  All participants must be follow the same regimen for surgery related medications, both
             pre and post surgery. (Antibiotic, NSAID and Steroid eye drops)

        Exclusion Criteria:

          -  Subjects requiring Premium IOLs/multifocal implants

          -  Advanced cataract

          -  Severe Age-Related Macular Degeneration Presence or history of Glaucoma

          -  Presence or history of Diabetes Mellitus

          -  Any Retinal pathology - retinal detachment, retinitis pigmentosa, diabetic
             retinopathy, etc

          -  Vision loss due to Central retinal artery occlusion or Central retinal vein occlusion

          -  Vision loss due to presence of large pituitary tumors or aneurysms

          -  Vision loss due to optic tract lesions

          -  Vision loss due to bleeding into aqueous or vitreous chamber

          -  Vision loss due to drug toxicity: Amiodarone, anti-tuberculosis drugs,
             hydroxychloroquine, tamoxifen

          -  Major cardiovascular or cerebral events in the past 12 months

          -  Allergy to fish oil or safflower oil

          -  Pregnancy or lactation at any time during the study

          -  Newly started or increased the dose of chronic systemic medication known to affect
             tear production including, but not limited to antihistamines, antidepressants,
             diuretics, corticosteroids or immunomodulators within 30 days of Screening or at any
             time during the study

          -  Participation in any other study involving an investigational drug or device within
             the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Crabtree</last_name>
      <phone>859-331-9000</phone>
      <phone_ext>4120</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Eye Associates</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Williams</last_name>
      <email>kim.williams@innovativeclinicalresearch.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

